OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
April 07, 2011
In France, it took a president's keynote speech to underscore the government's new understanding that there is more to pharmaceuticals than cost-containment
July 01, 2010
Focus Reports discusses kep questions regarding France's pharma industry
FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.
As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.
Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.
Drug prices, doctor payments, and FDA regulatory decisions are candidates for expanded disclosure.
Once occupied by a single pharma leader, the roles of CEO, president, and board chairman are increasingly being separated. What's behind the trend?
New strategies like augmented reality can increase patient compliance and knowledge.
Why do patients drop drug therapy after 12 months?
Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?
From the Editor
If there was ever a justification for endorsing a "triple bottom line" strategy for measuring Big Pharma's investment performance, it's the BP crisis.
Why pharma sales representatives are still the best marketers and how to make them better.